# Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia

> **NCT01408732** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Minnesota** · enrollment: 18 (actual)

## Conditions studied

- Epistaxis
- Hereditary Hemorrhagic Telangiectasia

## Interventions

- **DRUG:** Sclerotherapy
- **OTHER:** Standard Treatment

## Key facts

- **NCT ID:** NCT01408732
- **Lead sponsor:** University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2019-11-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01408732

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01408732, "Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01408732. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*